Retrovir IV (Zidovudine Injection) Drug Information: Overdosage and Contraindications

Pill Identifier Search

May 27, 2012

Retrovir IV

HIV and AIDS: Antiretroviral Drugs, Treatments and Medications »

Entry Inhibitors (including Fusion Inhibitors) and CCR5 Co-receptor Antagonist

Entry Inhibitors
Entry inhibitors block HIV entry into CD4+ cells.

Fusion inhibitors
The only drug in this class is T-20, which is administered as a twice daily subcutaneous injection. The most common side effect is redness and pain at the site of injection. Rarely, infection can occur at the injection site. There also are reports of generalized allergic reactions.

CCR5 antagonist
Although there were some early concerns of liver inflammation for drugs in this class, MVC appeared to be well tolerated in clinical trials without any specific toxicities attributable to the drug. However, it is a new drug in a new class and the first to actually target the cell. For these reasons, longer follow-up from clinical trials and those followed in the clinic will be very important for assessing the overall safety of the...

Read the HIV and AIDS: Antiretroviral Drugs, Treatments and Medications article »

« Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
Next »

Retrovir IV

HIV AIDS Myths and Facts Slideshow Pictures

Take the HIV/AIDS Quiz

AIDS Retrospective Slideshow Pictures

font size

OVERDOSE

Acute overdoses of zidovudine have been reported in pediatric patients and adults. These involved exposures up to 50 grams. No specific symptoms or signs have been identified following acute overdosage with zidovudine apart from those listed as adverse events such as fatigue, headache, vomiting, and occasional reports of hematological disturbances. All patients recovered without permanent sequelae. Hemodialysis and peritoneal dialysis appear to have a negligible effect on the removal of zidovudine, while elimination of its primary metabolite, GZDV, is enhanced.

CONTRAINDICATIONS

RETROVIR IV (zidovudine injection) Infusion is contraindicated for patients who have potentially life-threatening allergic reactions to any of the components of the formulation.

Last reviewed on RxList: 4/29/2009
This monograph has been modified to include the generic and brand name in many instances.